Entero Healthcare Solutions Share Price

Healthcare Services company Entero Healthcare Solutions announced Q4FY26 & FY26 results Consolidated Financial Highlights: The Company reported Revenue from operations of Rs 19,099.27 million in Q4FY26, witnessing a growth of 42.63% YoY compared to Rs 13,390.56 million in Q4FY25 and a growth of 11.92% QoQ from Rs 17,065.18 million in Q3FY26. Total Income for Q4FY26, stood at Rs 19,139.35 million, representing a YoY growth of 42.16% and a QoQ growth of 11.85%. Net Profit for the quarter (PAT) was Rs 451.28 million, reflecting an increase of 43.62% YoY from Rs 314.22 million and an increase of 33.21% QoQ from Rs 338.78 million. For FY26, Consolidated Revenue from operations reached Rs 65,912.12 million, marking a growth of 29.35% YoY compared to Rs 50,957.80 million in FY25. Annual Consolidated Total Income for FY26 stood at Rs 66,104.49 million, up 28.73% YoY from Rs 51,352.85 million in the previous year. The Annual Net Profit for FY26 was Rs 1,458.40 million, showing an increase of 35.75% YoY compared to Rs 1,074.34 million in FY25. The Company reported an Exceptional Item of Rs 81.78 million for FY26, related to incremental employee benefit liabilities arising from the New Labour Codes. Earnings per equity share (Basic) for FY26 increased to Rs 26.44 from Rs 21.80 in FY25. Standalone Financial Highlights: Standalone Revenue from operations for Q4FY26 stood at Rs 789.32 million, up 9.17% YoY from Rs 723.02 million, but witnessed a decline of 26.05% QoQ from Rs 1,067.36 million in Q3FY26. Total Income for the standalone entity in Q4FY26 was Rs 1,188.88 million, an increase of 21.10% YoY compared to Rs 981.76 million and a decrease of 8.54% QoQ. Standalone Net Profit (PAT) for Q4FY26 was Rs 134.16 million, compared to a loss of Rs 278.06 million in the corresponding quarter of the previous year. Annual Standalone Revenue from operations for FY26 was Rs 3,482.41 million, reflecting a decline of 14.79% YoY from Rs 4,086.70 million in FY25. The Annual Standalone Net Profit for FY26 was Rs 268.75 million, showing a growth of 40.11% YoY compared to Rs 191.81 million in FY25. Standalone Basic Earnings per share for FY26 was Rs 6.18, compared to Rs 4.41 in FY25. Business Highlights: Segment Performance: The Company operates in only one reportable business segment, which is the trading of pharmaceutical and surgical products. Acquisitions: During FY26, the Company entered into share purchase agreements with multiple entities including Ramson Medical Distributors Private Limited, Sai RK Pharma Private Limited, Well Wisher Pharma Private Limited, and Anand Medicine Private Limited, making them subsidiaries. Target Entity Performance: The Company approved the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals via its subsidiary. Vishal Surgicals reported a turnover of Rs 116.06 million in FY25, and Vishal Surgicals & Medicals reported a turnover of Rs 57.94 million in FY25. Investment and Funding: The Board approved an investment in a proposed Wholly Owned Subsidiary in the United States of America for an aggregate amount not exceeding Rs 3 crore. IPO Proceeds: As of March 31, 2026, the Company has fully utilized the IPO proceeds of Rs 9,548.00 million for purposes including repayment of borrowings (Rs 1,425.00 million), long-term working capital (Rs 4,800.00 million), and inorganic growth through acquisitions (Rs 2,370.00 million). Divestment: On September 28, 2025, the Company sold its entire equity shareholding in Suprabhat Pharmaceutical Private Limited, which subsequently ceased to be a subsidiary. Result PDF

• Trendlyne
• 1 day 9 hours ago

Conference Call with Entero Healthcare Solutions Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 1 day 10 hours ago

Healthcare Services company Entero Healthcare Solutions announced Q3FY26 results Total Income: Rs 1,706.5 crore against Rs 1,359 crore during Q3FY25, change 26%. EBITDA: Rs 67.8 crore against Rs 50 crore during Q3FY25, change 36%. EBITDA Margin: 4% for Q3FY26. PBT: Rs 40.4 crore against Rs 39.4 crore during Q3FY25, change 3%. PAT: Rs 33.9 crore against Rs 29.4 crore during Q3FY25, change 15%. EPS: Rs 6.35 for Q3FY26. Prabhat Agrawal Promoter, Managing Director & CEO, said: This was another quarter of solid growth where we achieved highest organic likefor-like growth rate (17.1%) year-to-date. Along with growth, we have also improved our cash flow performance and generated Rs 49 crore of operating cashflow during the quarter while maintaining EBITDA margin of 4%. We have closed all major acquisitions with emphasis on Medtech segment and are now strategically positioned to accelerate growth and deliver margin expansion in the near term. Result PDF

• Trendlyne
• 3 months 2 weeks ago